- Conditions
- Overweight and Obesity
- Interventions
- MM-based MI, healthy education
- Behavioral · Other
- Lead sponsor
- Michigan State University
- Other
- Eligibility
- 3 Years to 11 Years
- Enrollment
- 49 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- East Lansing, Michigan
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 481–504
of 719
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Primary Myelofibrosis (PMF), Post-Polycythaemia Vera, Essential Thrombocythaemia Myelofibrosis
- Interventions
- AZD1480
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 25 Years to 99 Years
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 2
- States / cities
- New York, New York • Houston, Texas
- Conditions
- Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma
- Interventions
- SONALA-001 (ALA) and MR-Guided Focused Ultrasound device (MRgFUS)
- Combination Product
- Lead sponsor
- SonALAsense, Inc.
- Industry
- Eligibility
- 5 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 3
- States / cities
- San Francisco, California • Washington D.C., District of Columbia • Miami, Florida
- Conditions
- Metastatic Solid Tumors
- Interventions
- ERAS-4001, ERAS-4001 in combination
- Drug
- Lead sponsor
- Erasca, Inc.
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 5
- States / cities
- Nashville, Tennessee • Houston, Texas • Irving, Texas + 2 more
- Conditions
- Acute Myeloid Leukemia, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera
- Interventions
- LNK01002
- Drug
- Lead sponsor
- Lynk Pharmaceuticals Co., Ltd
- Industry
- Eligibility
- 18 Years to 99 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 2
- States / cities
- Farmington Hills, Michigan • Sterling Heights, Michigan
- Conditions
- Psoriasis
- Interventions
- MOL4239, Placebo
- Drug
- Lead sponsor
- Moleculin, LLC
- Industry
- Eligibility
- 18 Years to 72 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013
- U.S. locations
- 3
- States / cities
- Miami, Florida • Fridley, Minnesota • Albuquerque, New Mexico
- Conditions
- Pancreatic Ductal Adenocarcinoma
- Interventions
- INNO-206
- Drug
- Lead sponsor
- ImmunityBio, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 6
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Santa Monica, California + 3 more
- Conditions
- Degenerative Disc Disease, Spondylolisthesis
- Interventions
- Prefix (AMPLEX) B2A Peptide Enhanced Ceramic Granules, Iliac crest autograft
- Device · Other
- Lead sponsor
- BioSurface Engineering Technologies, Inc
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 6
- States / cities
- Durango, Colorado • Washington D.C., District of Columbia • Kansas City, Kansas + 3 more
- Conditions
- Systemic Juvenile Idiopathic Arthritis
- Interventions
- rilonacept (IL-1 Trap), Placebo
- Drug · Other
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 4 Years to 20 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Wilmington, Delaware • Chicago, Illinois + 6 more
- Conditions
- Cardiac Electrophysiology
- Interventions
- Tetanizing Burst Therapy
- Device
- Lead sponsor
- EP Sciences
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Small Cell Lung Cancer, Advanced Solid Malignant Tumor
- Interventions
- Chiauranib
- Drug
- Lead sponsor
- Chipscreen Biosciences, Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 11
- States / cities
- Encinitas, California • Fullerton, California • Atlanta, Georgia + 8 more
- Conditions
- Ocular Inflammation and Pain After Cataract Surgery
- Interventions
- APP13007, 0.05%, APP13007, 0.1%, APP13007 Placebo, 0.05%, APP13007 Placebo, 0.1%
- Drug
- Lead sponsor
- Formosa Pharmaceuticals, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 165 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 9
- States / cities
- Phoenix, Arizona • Inglewood, California • Rancho Cordova, California + 5 more
- Conditions
- Pregnancy Related, Exercise, Sedentary Behavior, Behavior and Behavior Mechanisms
- Interventions
- Remotely-delivered health coaching intervention
- Behavioral
- Lead sponsor
- University of Iowa
- Other
- Eligibility
- 18 Years to 44 Years · Female only
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- HPV-Related Cervical Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma
- Interventions
- Two IM injections Lenti-HPV-07, One IM injection Lenti-HPV-07
- Drug
- Lead sponsor
- Theravectys S.A.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 4
- States / cities
- Orlando, Florida • Tampa, Florida • Tulsa, Oklahoma
- Conditions
- Malaria
- Interventions
- Group A FMP2.1/AS01B, Group B FMP2.1/AS02A
- Biological
- Lead sponsor
- U.S. Army Medical Research and Development Command
- Federal
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2007
- U.S. locations
- 1
- States / cities
- Silver Spring, Maryland
- Conditions
- Hemostasis, General Surgery
- Interventions
- sFilm-FS, TACHOSIL®
- Combination Product
- Lead sponsor
- Sealantium Medical Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Advanced Solid Tumor
- Interventions
- LM-24C5
- Drug
- Lead sponsor
- LaNova Medicines Limited
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Ocala, Florida • Indianapolis, Indiana + 3 more
- Conditions
- Advanced or Metastatic KRAS-mutant Tumor in Pancreatic Adenocarcinoma, Advanced or Metastatic KRAS-mutant Tumor in Colorectal Cancer, Advanced or Metastatic KRAS-mutant Tumor in Non Small Cell Lung Cancer, Advanced Solid Tumors, Advanced or Metastatic KRAS-mutant Tumor
- Interventions
- WEF-001
- Drug
- Lead sponsor
- Auricula Biosciences Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 2
- States / cities
- Dallas, Texas • San Antonio, Texas
- Conditions
- Hematologic Cancer
- Interventions
- ABBV-101, Venetoclax
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 135 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2031
- U.S. locations
- 14
- States / cities
- Tucson, Arizona • Orange, California • Palo Alto, California + 11 more
- Conditions
- Acne Vulgaris
- Interventions
- B244, Placebo
- Drug
- Lead sponsor
- AOBiome LLC
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Richardson, Texas
- Conditions
- Lymphoma, B-Cell
- Interventions
- CC-220, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, CC-99282, Polatuzumab vedotin
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 224 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Duarte, California + 12 more
- Conditions
- Depression - Major Depressive Disorder, Cannabis Use Disorder, Mental Disorder
- Interventions
- Amplification of Positivity - Cannabis Use (AMP-C)
- Behavioral
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Malignant Mesothelioma, Metastatic Malignant Solid Tumor, Advanced Solid Tumor
- Interventions
- ISM6331
- Drug
- Lead sponsor
- InSilico Medicine Hong Kong Limited
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 6
- States / cities
- Denver, Colorado • Chicago, Illinois • Cleveland, Ohio + 3 more
- Conditions
- Amyotrophic Lateral Sclerosis
- Interventions
- Fasudil (WP-0512)
- Drug
- Lead sponsor
- Woolsey Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2029
- U.S. locations
- 9
- States / cities
- Phoenix, Arizona • Aurora, Colorado • Denver, Colorado + 6 more